Furthermore, TP53, a tumor suppressor gene and the most frequently mutated gene in human cancer, displays a 71% mutation rate within high SGO2 clusters.50 Although there is no recommended medication available for TP53 mutations, our study demonstrates that high SGO2 clusters are more responsive to chemotherapy and targeted therapies, with lower IC50 values for Paclitaxel, Cisplatin, Docetaxel, Erlotinib, Gefitinib, and Osimertinib. Here, SGO2 is linked to cancer.